Drug Topics January 13, 2025
Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.
Glucagon-like peptide-1 (GLP-1) receptor agonists have proved to be the definitive standard of practice for the treatment of patients living with obesity and type 2 diabetes (T2D). However, with several variations of the medication entering the prescription drug market, it’s important for pharmacists to understand their patients’ needs and know how different GLP-1s will impact specific patient outcomes.
“Everyone is talking about tirzepatide and semaglutide, which have revolutionized the management of T2D and obesity. Tirzepatide offers very high efficacy for weight loss (more than semaglutide, based on recent evidence) most likely due to its dual mechanism, while semaglutide has established...
Today's Sponsors
Today's Sponsor